Organon & Co. (NYSE:OGN - Get Free Report) hit a new 52-week high on Monday. The stock traded as high as $13.91 and last traded at $13.9050, with a volume of 3,534,006 shares traded. The stock had previously closed at $13.90.
Analyst Ratings Changes
Separately, Weiss Ratings raised shares of Organon & Co. from a "hold (c-)" rating to a "hold (c)" rating in a research report on Thursday, October 8th. Four equities research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Reduce" and a consensus price target of $12.00.
Get Our Latest Stock Analysis on OGN
Organon & Co. Trading Up 0.0%
The company has a market cap of $3.65 billion, a price-to-earnings ratio of 18.30, a price-to-earnings-growth ratio of 1.28 and a beta of 1.53. The firm has a 50-day moving average price of $13.76 and a 200 day moving average price of $11.71. The company has a current ratio of 2.02, a quick ratio of 1.51 and a debt-to-equity ratio of 7.11.
Organon & Co. (NYSE:OGN - Get Free Report) last released its quarterly earnings data on Friday, October 30th. The company reported $0.94 EPS for the quarter, topping analysts' consensus estimates of $0.88 by $0.06. Organon & Co. had a net margin of 3.49% and a return on equity of 82.06%. The firm had revenue of $1.57 billion during the quarter, compared to the consensus estimate of $1.58 billion. As a group, sell-side analysts forecast that Organon & Co. will post 3.24 EPS for the current year.
Organon & Co. Dividend Announcement
The business also recently announced a quarterly dividend, which will be paid on Thursday, December 10th. Stockholders of record on Monday, November 9th will be issued a dividend of $0.02 per share. The ex-dividend date of this dividend is Monday, November 9th. This represents a $0.08 annualized dividend and a dividend yield of 0.6%. Organon & Co.'s dividend payout ratio is 10.53%.
Institutional Trading of Organon & Co.
A number of large investors have recently modified their holdings of OGN. California State Teachers Retirement System lifted its stake in shares of Organon & Co. by 34.8% in the 1st quarter. California State Teachers Retirement System now owns 327,075 shares of the company's stock worth $1,959,000 after acquiring an additional 84,497 shares during the period. WINTON GROUP Ltd bought a new stake in shares of Organon & Co. during the 2nd quarter worth $6,904,000. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new position in Organon & Co. in the 2nd quarter worth about $770,000. Orographic Financial Advisors LLC purchased a new position in shares of Organon & Co. in the first quarter worth approximately $1,522,000. Finally, Sei Investments Co. grew its position in Organon & Co. by 82.0% during the 1st quarter. Sei Investments Co. now owns 190,057 shares of the company's stock worth $1,139,000 after purchasing an additional 85,657 shares in the last quarter. Institutional investors and hedge funds own 77.43% of the company's stock.
About Organon & Co.
(
Get Free Report)
Organon & Co. is a global health care company focused on women's health, biosimilars and established medicines. It develops and markets prescription medicines and other health products for patients and health care professionals. Its women's health portfolio includes contraceptive and fertility products, while its biosimilars business offers biologic medicines in areas such as immunology and oncology. The company also sells established medicines across several therapeutic areas, including cardiovascular health, respiratory conditions and dermatology.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Organon & Co., you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Organon & Co. wasn't on the list.
While Organon & Co. currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.